These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33872419)

  • 1. A single-centre real-life experience on effectiveness and safety of dupilumab in adolescents with severe atopic dermatitis in treatment with cyclosporine A.
    Colonna C; Zussino M; Ponziani A; Gelmetti C; Monzani NA
    J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):e533-e535. PubMed ID: 33872419
    [No Abstract]   [Full Text] [Related]  

  • 2. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
    Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
    Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Gurioli C; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Esposito M; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e384-e388. PubMed ID: 36225088
    [No Abstract]   [Full Text] [Related]  

  • 4. A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab.
    D'Adamio S; Massaro A; Biocca S; Bianchi L; Talamonti M; Galluzzo M
    Clin Exp Dermatol; 2020 Aug; 45(6):809-810. PubMed ID: 32472943
    [No Abstract]   [Full Text] [Related]  

  • 5. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study.
    Napolitano M; Fabbrocini G; Scalvenzi M; Blasio C; Stingeni L; Patruno C
    Clin Exp Dermatol; 2020 Oct; 45(7):888-890. PubMed ID: 32365237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study.
    Gargiulo L; Vignoli CA; Ibba L; Cortese A; Valenti M; Costanzo A; Narcisi A
    J Dermatolog Treat; 2023 Apr; 34(1):2200867. PubMed ID: 37026618
    [No Abstract]   [Full Text] [Related]  

  • 9. A review of dupilumab in the treatment of atopic diseases.
    Thibodeaux Q; Smith MP; Ly K; Beck K; Liao W; Bhutani T
    Hum Vaccin Immunother; 2019; 15(9):2129-2139. PubMed ID: 30785362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy of systemic treatments for atopic dermatitis.
    Seger EW; Wechter T; Strowd L; Feldman SR
    J Am Acad Dermatol; 2019 Feb; 80(2):411-416.e4. PubMed ID: 30296535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report.
    Uchida H; Kamata M; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    Acta Derm Venereol; 2019 Jun; 99(7):675-676. PubMed ID: 30938821
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
    Siegfried EC; Bieber T; Simpson EL; Paller AS; Beck LA; Boguniewicz M; Schneider LC; Khokhar FA; Chen Z; Prescilla R; Mina-Osorio P; Bansal A
    Am J Clin Dermatol; 2021 Mar; 22(2):243-255. PubMed ID: 33655423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.
    Stingeni L; Hansel K; Antonelli E; Bello GD; Patruno C; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G
    Dermatol Ther; 2021 Sep; 34(5):e15035. PubMed ID: 34152670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
    Guédon C; Tauber M; Linder C; Paul C; Shourick J
    Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis.
    Giavina-Bianchi M; Giavina-Bianchi P
    Einstein (Sao Paulo); 2021; 19():eRC6064. PubMed ID: 33978100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial.
    Merola JF; Sidbury R; Wollenberg A; Chen Z; Zhang A; Shumel B; Rossi AB
    J Am Acad Dermatol; 2021 Feb; 84(2):495-497. PubMed ID: 32387659
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: a preliminary report of real-world data.
    Ferrucci SM; Maronese CA; Tavecchio S; Angileri L; Genovese G; Marzano AV
    Ital J Dermatol Venerol; 2022 Apr; 157(2):211-213. PubMed ID: 35391535
    [No Abstract]   [Full Text] [Related]  

  • 20. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Peccianti C; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavo SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Stingeni L; Caruso C; Argenziano G;
    J Dermatolog Treat; 2022 Mar; 33(2):1146-1149. PubMed ID: 32436765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.